Finanzas de Cue Biopharma Inc (CUE)CUECue Biopharma Inc

Evaluating the bottom line, Cue Biopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1113.30%, while the net margin is -1943.21%. These profitability ratios, combined with a Return on Equity (ROE) of -1603.48%, provide a clear picture of how effectively CUE converts its operational activities into shareholder value.

In the context of the broader market, CUE competes directly with industry leaders such as ARMP and VRXA. With a market capitalization of $206.60M, it holds a leading position in the sector. When comparing efficiency, CUE's gross margin of 100.00% stands against ARMP's 100.00% and VRXA's N/A. Such benchmarking helps identify whether Cue Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

Cue Biopharma has shown substantial revenue growth, with Q2 2026 revenue reaching $7.88 million, up from $2.95 million a year ago. Despite this, the company reported a significant net loss of $153.07 million for the same quarter, highlighting financial challenges.